Evogene (EVGN) Tops Q4 EPS by 1c

Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $580 thousand versus the consensus estimate of $893.33 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• MIND Technology (MIND) Misses Q1 EPS by 5c